Indeed, ALK inhibitors, such as crizotinib, have been shown to have therapeutic effects in clinical trials for lung cancer (systematically reviewed in [46]), inflammatory myofibroblastic tumors, a rare mesenchymal neoplasm [47] and anaplastic large-cell lymphoma [48]. Here, ALK is linked to mesenchymal cell neoplasm.